Recro Pharma Balance Sheet - Annual (NASDAQ:REPH)

Add to My Stocks
$7.5 $0.09 (1.21%) REPH stock closing price Sep 19, 2018 (Closing)

The fundamental analysis of this company requires a thorough look at Recro Pharma balance sheet. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Recro Pharma stock analysis, and provides insights into the firm's financial performance. Annual results are typically accompanied with the company releasing financial statements. Recro Pharma had a long term debt of $53.59M at the end of 2017. To understand the debt servicing capacity of the company, one needs to look at Recro Pharma operating cash flow and Recro Pharma revenue also. Recro Pharma debt to equity ratio is 2.22.

View latest 10 year balance sheet data to check Recro Pharma financial performance.
show more
Fiscal year is Jan - Dec20172016201520142013
Marketable Securities3.49M----
Raw Materials2.13M2.55M2.93M--
Work In Progress3.93M4.39M4.34M--
Finished Goods4.48M1.79M1.7M--
Notes Receivable-----
Other Current Assets3.27M1.11M1.29M--
Total Current Assets
Property Plant & Equipment52.89M46.42M42.05M--
Accumulated Depreciation13.82M9.12M4.13M--
Net Property Plant & Equipment
Investment & Advances-----
Other Non-Current Assets-----
Deferred Charges18.57M17.06M15.63M--
Deposits & Other Assets-----
Total Assets
Notes Payable----11.9M
Accounts Payable7.95M4.13M1.55M--
Current Portion Long-Term Debt-2.23M4.51M--
Current Portion Capital Leases-----
Accrued Expenses9.89M9.89M3.41M--
Income Taxes Payable-----
Other Current Liabilities32.05M----
Total Current Liabilities
Deferred Taxes/Income-----
Convertible Debt-----
Long-Term Debt53.59M22.15M25.24M--
Non-Current Capital Leases-----
Other Long-Term Liabilities53.87M72.97M63.61M--
Total Liabilities
Minority Interest-----
Preferred Stock----5.88M
Common Stock Net-----
Capital Surplus140M132.69M71.32M52.94M-
Retained Earnings-111.34M-61.26M-31.06M-34.09M-17.96M
Treasury Stock-----
Other Liabilities-----
Shareholders Equity28.84M71.61M40.35M18.92M-12.07M
Total Liabilities & Shareholders Equity186.22M182.99M138.69M20.37M-
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our AcelRx Pharma financial analysis

Looking at Recro Pharma historical stock prices and the current Recro Pharma stock price can tell you how the stock price has moved, whereas the Recro Pharma PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:

  • Assets: An asset is a resource that a corporation like Recro Pharma owns and has monetary significance. REPH assets grew from $182.99M in 2016 to $186.22M in 2017. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Recro Pharma is $157.37M. Shareholders' equity comes under liabilities as it is money the company owes the holders of REPH stock.

Recro Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio